Who owns Scinai Immunotherapeutics Ltd.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SCNI from SEC Form 13F filings across 11 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 11 institutions disclosed 190,004 shares of Scinai Immunotherapeutics Ltd. worth $41,084 — about 0.3% of shares outstanding; the largest disclosed holder is CITADEL ADVISORS LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
11
13F holders
$41,084
value, 2026 filers
0.3%
of shares outstanding (190,004 sh)
7
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SCNI's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLCNEW | 62,257 | $15,726 | 0.0% | 0.1% | new |
| 2 | ARMISTICE CAPITAL, LLCNEW | 35,942 | $9,079 | 0.0% | 0.1% | new |
| 3 | Virtu Financial LLCNEW | 19,485 | $5 | 0.0% | 0% | new |
| 4 | XTX Topco Ltd | 16,764 | $4,235 | 0.0% | 0% | -30.3% |
| 5 | RHUMBLINE ADVISERS | 13,513 | $3,417 | 0.0% | 0% | +619.5% |
| 6 | StoneX Group Inc.NEW | 13,092 | $4,563 | 0.0% | 0% | new |
| 7 | HRT FINANCIAL LPNEW | 12,088 | $3 | 0.0% | 0% | new |
| 8 | CAPTRUST FINANCIAL ADVISORSNEW | 12,035 | $3,040 | 0.0% | 0% | new |
| 9 | UBS Group AG | 3,955 | $1,001 | 0.0% | 0% | +330.4% |
| 10 | ROYAL BANK OF CANADANEW | 815 | $0 | 0.0% | 0% | new |
| 11 | MORGAN STANLEY | 58 | $15 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.